Supplementary Table 1: Drug concentrations used in the primary cultures and their respective clinically-relevant concentrations, when available

Drugs	Concentrations used in primary cultures	Clinically-relevant concentrations
Everolimus	10 nM	8 nM – 59 nM (1)
Capivasertib	5 µM, 10 µM	3.12 µM (2)
Alpelisib	5 µM	2 µM – 11 µM (3)
Ribociclib	20 µM	6.9 µM – 7.2 µM (4)
Sunitinib	0.5 µM	0.1 µM – 0.2 µM (5)
Cabozantinib	1 µM, 2.5 µM, 5 µM	0.7 µM – 2.2 µM (6)
Niraparib	5 µM	2.4 µM – 4.4 µM (7)
Adavosertib	10 µM	439 nM – 2.1 µM (8)
Berzosertib	1 µM, 10 µM	1.9 µM (9)
Temozolomide	100 µM	29.4 µM – 71.6 µM (10)
5-Fluorouracil	20 µM	0.19 µM – 192 µM (11)
Lurbinectedin	750 pM, 130 nM	136 nM (ZEPZELCA® labelling information)
Belzutifan	4 µM, 5 µM, 20 µM	3.5 µM – 4.7 µM (12)
Entinostat	1 µM	0.23 µM – 0.46 µM (13)
Onalespib	1 µM, 10 µM	0.1 µM - 1.4 µM (14)
PRI-724 (5 µM)	5 µM, 10 µM	1.8 µM - 5.4 µM (15)
Semaglutide (100 nM)	100 nM, 1 µM	15 nM (16)
Teduglutide (10 nM)	10 nM, 50 nM	5 nM – 20 nM (17)
Zoledronic acid (5 µM)	5 µM, 10 µM	1 µM – 8.3 µM (18)
Oestradiol (300 nM)	300 nM, 1 µM	0.003 – 0.28 µM (19)
Progesterone (1 µM)	1 µM, 10 µM	0.3 µM – 0.68 µM (20)
Testosterone (30 nM)	30 nM, 1 µM	32 nM (19)
DHEAS (1 µM)	1 µM, 10 µM	0.4 µM – 16 µM (19)
Prolactin (20 nM)	20 nM	0.4 µM – 26 nM (21)
Oxytocin (1 nM)	1 nM, 10 nM	17 pM - 84 pM (22)

References:

1. Budde K, Zonnenberg BA, Frost M, Cheung W, Urva S, Brechenmacher T, et al. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br J Clin Pharmacol. 2016;81(5):958-70.
2. Fernandez-Teruel C, Cullberg M, Eberlein C, Barry ST, Zhou D. Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clin Pharmacokinet. 2024;63(8):1191-204.

3. De Buck SS, Jakab A, Boehm M, Bootle D, Juric D, Quadt C, et al. Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. Br J Clin Pharmacol. 2014;78(3):543-55.
4. Schlam I, Smith DM, Peer C, Sissung T, Schmidt KT, Tan M, et al. Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study. NPJ Breast Cancer. 2024;10(1):84.
5. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35.
6. Miles D, Jumbe NL, Lacy S, Nguyen L. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis. Clin Pharmacokinet. 2016;55(1):93-105.
7. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882-92.
8. Nagard M, Ah-See ML, So K, Vermunt M, Thistlethwaite F, Labots M, et al. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020;86(1):97-108.
9. Plummer R, Dean E, Arkenau HT, Redfern C, Spira AI, Melear JM, et al. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 2022;163:19-26.
10. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81(6):1022-30.
11. Findlay MP, Raynaud F, Cunningham D, Iveson A, Collins DJ, Leach MO. Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha. Ann Oncol. 1996;7(1):47-53.
12. Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021;27(5):802-5.
13. Batlevi CL, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, et al. ENGAGE-501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica. 2016;101(8):968-75.
14. Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, et al. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022;126(7):1027-36.
15. Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP/beta-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine. 2022;80:104069.

16. Granhall C, Sondergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clin Pharmacokinet. 2018;57(12):1571-80.
17. Marier JF, Jomphe C, Peyret T, Wang Y. Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome. Clin Transl Sci. 2021;14(6):2497-509.
18. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228-36.
19. Troisi R, Potischman N, Roberts JM, Harger G, Markovic N, Cole B, et al. Correlation of serum hormone concentrations in maternal and umbilical cord samples. Cancer Epidemiol Biomarkers Prev. 2003;12(5):452-6.
20. Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso HA, Idahl A, et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth. 2016;16(1):146.
21. Sadovsky E, Weinstein D, Ben-David M, Polishuk WZ. Serum prolactin in normal and pathologic pregnancy. Obstet Gynecol. 1977;50(5):559-61.
22. Uvnas-Moberg K, Ekstrom-Bergstrom A, Berg M, Buckley S, Pajalic Z, Hadjigeorgiou E, et al. Maternal plasma levels of oxytocin during physiological childbirth - a systematic review with implications for uterine contractions and central actions of oxytocin. BMC Pregnancy Childbirth. 2019;19(1):285.